SV2006002143A - Uso de un anticuerpo para el tratamiento del cancer resistente al platino - Google Patents
Uso de un anticuerpo para el tratamiento del cancer resistente al platinoInfo
- Publication number
- SV2006002143A SV2006002143A SV2005002143A SV2005002143A SV2006002143A SV 2006002143 A SV2006002143 A SV 2006002143A SV 2005002143 A SV2005002143 A SV 2005002143A SV 2005002143 A SV2005002143 A SV 2005002143A SV 2006002143 A SV2006002143 A SV 2006002143A
- Authority
- SV
- El Salvador
- Prior art keywords
- platinum
- treatment
- antibody
- cancer resistant
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
LA PRESENTE INVECION SE REFIERE A USO DE UN ANTICUERPO HER2 QUE INHIBE LA DIMERIZACION MAS EFICAZMENTE QUE TRASNTUZUMAB Y UN AGENTE ANTIMETABOLITO EN LA PREPARACION DE UNA MEDICINA PARA EL TRATAMIENTO DEL CANCER RESISTENTE AL PLATINO, SELECCIONADO DE UN GRUPO CONSISTENTE EN EL CANCER DEL OVARIO EL CARCINOMA PRIMARIO DEL PERITONEO Y EL CARCINOMA DE LAS TROMPAS DE FALOPIO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58033304P | 2004-06-16 | 2004-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2006002143A true SV2006002143A (es) | 2006-01-26 |
Family
ID=35432102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2005002143A SV2006002143A (es) | 2004-06-16 | 2005-06-14 | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
Country Status (28)
Country | Link |
---|---|
US (2) | US20060013819A1 (es) |
EP (1) | EP1755671B1 (es) |
JP (3) | JP2008503476A (es) |
KR (3) | KR20130038407A (es) |
CN (2) | CN101014366A (es) |
AR (1) | AR049305A1 (es) |
AU (2) | AU2005262459B2 (es) |
BR (1) | BRPI0511377A (es) |
CA (1) | CA2567808C (es) |
DK (1) | DK1755671T3 (es) |
ES (1) | ES2398689T3 (es) |
GT (1) | GT200500155A (es) |
HK (1) | HK1102757A1 (es) |
IL (1) | IL179401A (es) |
JO (1) | JO2794B1 (es) |
MX (1) | MXPA06014687A (es) |
MY (1) | MY163024A (es) |
NO (1) | NO20070243L (es) |
NZ (1) | NZ551376A (es) |
PA (1) | PA8637101A1 (es) |
PE (1) | PE20060461A1 (es) |
PL (1) | PL1755671T3 (es) |
RU (1) | RU2403065C2 (es) |
SI (1) | SI1755671T1 (es) |
SV (1) | SV2006002143A (es) |
TW (1) | TWI375564B (es) |
WO (1) | WO2006007398A1 (es) |
ZA (1) | ZA200610132B (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
PL400669A1 (pl) * | 2000-05-19 | 2012-11-05 | Genentech, Inc. | Genowa próba wykrywania odpowiedzi na antagoniste ErbB dla poprawienia prawdopodobienstwa i skutecznosci leczenia raka |
RU2361880C2 (ru) | 2004-07-22 | 2009-07-20 | Дженентек, Инк. | Композиция антител к her2 |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
JP2008523073A (ja) * | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Her阻害剤を用いた治療のための患者の選択 |
PL1846030T3 (pl) * | 2005-01-21 | 2019-05-31 | Genentech Inc | Ustalone dawkowanie przeciwciał her |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
LT2301531T (lt) | 2005-02-18 | 2018-09-25 | Abraxis Bioscience, Llc | Terapinių agentų deriniai bei įvedimo būdai ir kombinuotas gydymas |
MX2007009889A (es) * | 2005-02-23 | 2007-09-07 | Genentech Inc | Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer. |
PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
EP2094268A2 (en) * | 2006-05-26 | 2009-09-02 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
JP2009539836A (ja) * | 2006-06-05 | 2009-11-19 | ジェネンテック・インコーポレーテッド | EGFまたはTGF−αのレベルの上昇が生じている癌患者の生存の延長 |
WO2011008990A1 (en) | 2009-07-15 | 2011-01-20 | Prometheus Laboratories Inc. | Drug selection for gastric cancer therapy using antibody-based arrays |
BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
CN104586815A (zh) | 2006-12-14 | 2015-05-06 | 阿布拉科斯生物科学有限公司 | 用包含紫杉烷的纳米颗粒基于激素受体状态治疗乳腺癌 |
EP2899541A1 (en) * | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
CA2716826C (en) | 2008-02-25 | 2017-05-09 | Prometheus Laboratories Inc. | Drug selection for breast cancer therapy using antibody-based arrays |
JP2010006705A (ja) * | 2008-06-13 | 2010-01-14 | Atlas Antibodies Ab | Her2サブセット |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
JP2012507299A (ja) | 2008-10-31 | 2012-03-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Light標的分子およびその使用 |
AU2010233993A1 (en) | 2009-04-07 | 2011-09-08 | Roche Glycart Ag | Bispecific anti-ErbB-1/anti-c-Met antibodies |
US10143652B2 (en) * | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
US9402812B2 (en) * | 2009-09-23 | 2016-08-02 | Indu JAVERI | Methods for the preparation of liposomes |
RU2580038C2 (ru) * | 2009-12-04 | 2016-04-10 | Дженентек, Инк. | Мультиспецифические антитела, аналоги антител, композиции и способы |
US8937159B2 (en) * | 2009-12-16 | 2015-01-20 | Abbvie Biotherapeutics Inc. | Anti-HER2 antibodies and their uses |
MX369170B (es) * | 2010-02-23 | 2019-10-30 | Genentech Inc | Combinación concurrente de un anticuerpo anti-vegf con carboplatino y gemcitabina para usarse en el tratamiento de cáncer ovárico. |
CA3087813A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of treating cancer |
KR20190109593A (ko) | 2010-03-29 | 2019-09-25 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
KR20190038684A (ko) | 2010-06-04 | 2019-04-08 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
WO2012154809A1 (en) * | 2011-05-09 | 2012-11-15 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
KR101851425B1 (ko) | 2011-09-02 | 2018-04-23 | 네스텍 소시에테아노님 | 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링 |
RS58944B1 (sr) | 2011-10-14 | 2019-08-30 | Hoffmann La Roche | Pertuzumab, trastuzumab, docetaksel i karboplatin za lečenje raka dojke u ranoj fazi |
JP6187960B2 (ja) * | 2012-01-20 | 2017-08-30 | 日本製粉株式会社 | がんの治療又は予防剤 |
JP6563197B2 (ja) * | 2012-03-13 | 2019-08-21 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 卵巣癌の治療のための併用療法 |
EP2638916A1 (en) * | 2012-03-16 | 2013-09-18 | Covagen AG | Novel binding molecules with antitumoral activity |
CN104284675B (zh) * | 2012-03-16 | 2017-07-18 | 科瓦根股份公司 | 具有抗肿瘤活性的新颖结合分子 |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
US20160067182A1 (en) * | 2013-04-09 | 2016-03-10 | Merrimack Pharmaceuticals, Inc. | Methods and compositions for improving outcomes of liposomal chemotherapy |
CN105121471A (zh) | 2013-04-16 | 2015-12-02 | 豪夫迈·罗氏有限公司 | 帕妥珠单抗变体及其评估 |
WO2014208760A1 (ja) * | 2013-06-27 | 2014-12-31 | 国立大学法人九州大学 | 抗がんモノクローナル抗体及びその製造方法 |
CN104726462A (zh) * | 2013-12-20 | 2015-06-24 | 北京天广实生物技术股份有限公司 | 抗her2人源化抗体mil41、其制备方法及用途 |
MX2016014007A (es) | 2014-04-25 | 2017-01-11 | Genentech Inc | Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab. |
US10385380B2 (en) | 2014-10-02 | 2019-08-20 | The Regents Of The University Of California | Personalized protease assay to measure protease activity in neoplasms |
WO2016196373A2 (en) | 2015-05-30 | 2016-12-08 | Genentech, Inc. | Methods of treating her2-positive metastatic breast cancer |
US9770462B2 (en) | 2015-10-05 | 2017-09-26 | National Cheng Kung University | Method of treating ovarian, tubal and peritoneal cancer |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
FI127460B (en) * | 2016-01-15 | 2018-06-29 | Targovax Oy | COMBINATION OF ADENOVIRUS AND CHEMOTHERAPY AGENTS FOR CANCER CARE |
MX2019005144A (es) | 2016-11-04 | 2019-10-14 | Genentech Inc | Tratamiento de cáncer de mama positivo para her2. |
JP6914336B2 (ja) | 2016-12-28 | 2021-08-04 | ジェネンテック, インコーポレイテッド | 進行したher2発現がんの治療 |
MX2019008350A (es) | 2017-01-17 | 2019-11-11 | Genentech Inc | Formulaciones de anticuerpos de her2 subcutáneas. |
CN116531511A (zh) | 2017-03-02 | 2023-08-04 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
CA3059241A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
RU2738167C1 (ru) * | 2020-06-08 | 2020-12-09 | федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации | Способ определения эффективности химиотерапии препаратами платины при раке яичников III-IV стадии |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5824311A (en) * | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6884418B1 (en) * | 1989-08-04 | 2005-04-26 | Berlex Laboratories, Inc. | Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
DK0590058T3 (da) * | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
CA2134773A1 (en) | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US6287784B1 (en) | 1993-11-23 | 2001-09-11 | Genentech, Inc. | Kinase receptor activation assay |
DE69408541T2 (de) | 1993-11-23 | 1998-08-06 | Genentech Inc | Kinaserezeptoraktivierungstest |
EP0730646A1 (en) | 1993-11-23 | 1996-09-11 | Genentech, Inc. | PROTEIN TYROSINE KINASES NAMED Rse |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
EP1064027B1 (en) * | 1998-03-27 | 2008-06-18 | Genentech, Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
JP4469933B2 (ja) * | 1998-05-06 | 2010-06-02 | ジェネンテック, インコーポレイテッド | イオン交換クロマトグラフィによるタンパク質精製 |
CA2727172A1 (en) * | 1999-05-26 | 2001-01-04 | Genentech, Inc. | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
DE60033658T2 (de) * | 1999-06-25 | 2007-11-22 | Genentech, Inc., South San Francisco | Behandlung von prostata-krebs mit anti-erbb2 antikörpern |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US7041292B1 (en) * | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
KR20090126330A (ko) * | 1999-08-27 | 2009-12-08 | 제넨테크, 인크. | 항-ErbB2 항체 투여 치료 방법 |
US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
PL400669A1 (pl) * | 2000-05-19 | 2012-11-05 | Genentech, Inc. | Genowa próba wykrywania odpowiedzi na antagoniste ErbB dla poprawienia prawdopodobienstwa i skutecznosci leczenia raka |
JP2004002211A (ja) * | 2001-04-27 | 2004-01-08 | Takeda Chem Ind Ltd | 癌の予防・治療方法 |
US20030190689A1 (en) | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
GB0215593D0 (en) * | 2002-07-05 | 2002-08-14 | Univ Leeds | New anticancer drugs |
CN101711866A (zh) * | 2002-07-15 | 2010-05-26 | 健泰科生物技术公司 | 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法 |
US20040258685A1 (en) * | 2002-11-21 | 2004-12-23 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies |
AU2005232657B2 (en) * | 2004-04-08 | 2010-12-16 | David B. Agus | ErbB antagonists for pain therapy |
NZ579482A (en) * | 2004-06-01 | 2011-02-25 | Genentech Inc | Antibody drug conjugates and methods |
NZ551406A (en) * | 2004-06-03 | 2010-03-26 | Hoffmann La Roche | Treatment of non small cell lung cancer with gemcitabine and erlotinib (an egfr kinase inhibitor) |
RU2361880C2 (ru) * | 2004-07-22 | 2009-07-20 | Дженентек, Инк. | Композиция антител к her2 |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
JP2008523073A (ja) * | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Her阻害剤を用いた治療のための患者の選択 |
PL1846030T3 (pl) * | 2005-01-21 | 2019-05-31 | Genentech Inc | Ustalone dawkowanie przeciwciał her |
MX2007009889A (es) * | 2005-02-23 | 2007-09-07 | Genentech Inc | Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer. |
WO2006096861A2 (en) * | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
US9135948B2 (en) | 2009-07-03 | 2015-09-15 | Microsoft Technology Licensing, Llc | Optical medium with added descriptor to reduce counterfeiting |
-
2005
- 2005-06-14 SV SV2005002143A patent/SV2006002143A/es not_active Application Discontinuation
- 2005-06-14 GT GT200500155A patent/GT200500155A/es unknown
- 2005-06-15 AR ARP050102455A patent/AR049305A1/es unknown
- 2005-06-15 CN CNA2005800279305A patent/CN101014366A/zh active Pending
- 2005-06-15 MX MXPA06014687A patent/MXPA06014687A/es active IP Right Grant
- 2005-06-15 KR KR1020137005305A patent/KR20130038407A/ko not_active Application Discontinuation
- 2005-06-15 JO JO200588A patent/JO2794B1/en active
- 2005-06-15 DK DK05761257.4T patent/DK1755671T3/da active
- 2005-06-15 PA PA20058637101A patent/PA8637101A1/es unknown
- 2005-06-15 JP JP2007516733A patent/JP2008503476A/ja active Pending
- 2005-06-15 PL PL05761257T patent/PL1755671T3/pl unknown
- 2005-06-15 WO PCT/US2005/021286 patent/WO2006007398A1/en active Application Filing
- 2005-06-15 TW TW094119914A patent/TWI375564B/zh not_active IP Right Cessation
- 2005-06-15 KR KR1020137034789A patent/KR101517715B1/ko not_active IP Right Cessation
- 2005-06-15 SI SI200531668T patent/SI1755671T1/sl unknown
- 2005-06-15 BR BRPI0511377-6A patent/BRPI0511377A/pt not_active IP Right Cessation
- 2005-06-15 PE PE2005000682A patent/PE20060461A1/es not_active Application Discontinuation
- 2005-06-15 RU RU2007101378/14A patent/RU2403065C2/ru not_active IP Right Cessation
- 2005-06-15 ZA ZA200610132A patent/ZA200610132B/xx unknown
- 2005-06-15 US US11/154,337 patent/US20060013819A1/en not_active Abandoned
- 2005-06-15 CA CA2567808A patent/CA2567808C/en not_active Expired - Fee Related
- 2005-06-15 CN CN201510684542.XA patent/CN105194667A/zh active Pending
- 2005-06-15 KR KR1020077000952A patent/KR20070029804A/ko not_active Application Discontinuation
- 2005-06-15 ES ES05761257T patent/ES2398689T3/es active Active
- 2005-06-15 EP EP05761257A patent/EP1755671B1/en active Active
- 2005-06-15 NZ NZ551376A patent/NZ551376A/en not_active IP Right Cessation
- 2005-06-15 AU AU2005262459A patent/AU2005262459B2/en not_active Ceased
- 2005-06-15 MY MYPI20052703A patent/MY163024A/en unknown
-
2006
- 2006-11-20 IL IL179401A patent/IL179401A/en not_active IP Right Cessation
-
2007
- 2007-01-15 NO NO20070243A patent/NO20070243L/no not_active Application Discontinuation
- 2007-08-20 HK HK07109063.6A patent/HK1102757A1/xx not_active IP Right Cessation
-
2011
- 2011-03-03 AU AU2011200947A patent/AU2011200947A1/en not_active Abandoned
- 2011-12-01 US US13/309,206 patent/US20120107391A1/en not_active Abandoned
-
2012
- 2012-09-21 JP JP2012208489A patent/JP2013014611A/ja active Pending
-
2015
- 2015-04-09 JP JP2015079987A patent/JP2015157831A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2006002143A (es) | Uso de un anticuerpo para el tratamiento del cancer resistente al platino | |
AR075982A1 (es) | Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion | |
CL2018000319A1 (es) | Coadyuvantes basados en aceite (divisional de solicitud 201600650) | |
AR109246A2 (es) | USO DE UN INMUNOCONJUGADO QUE COMPRENDE UN ANTICUERPO ANTI-ErbB2 PARA LA MANUFACTURA DE UN MEDICAMENTO | |
PA8635501A1 (es) | Uso de un anticuerpo para el tratamiento del lupus | |
DOP2016000133A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
ECSP088778A (es) | Formulacion de un anticuerpo monoclonal humano anti-igf-1r | |
GT201700056A (es) | Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico. | |
AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
PE20180131A1 (es) | Terapia de combinacion del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte programada 1 (pd 1) para el tratamiento del cancer | |
CL2008002207A1 (es) | Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04). | |
ECSP088753A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
CL2008001335A1 (es) | Compuestos derivados de pirrolopirimidin-7-ona, antagonistas de los receptores de purina p2x; porceso de preparacion de estos; composicion farmaceutica que los comprende; proceso de preparacion de compuestos intermediarios y usos en el tratamientos del dolor, vejiga hiperactiva, entre otras. | |
CY1112721T1 (el) | Νεοι συνδετες που διαμορφωνουν τους υποδοχεις rαr, και χρηση αυτων στην ιατρικη για τον ανθρωπο και στα καλλυντικα | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
SV2011003939A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
ECSP109934A (es) | Compuesto - 946 | |
CO7200273A2 (es) | Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
CL2008003537A1 (es) | Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor. | |
WO2015050959A8 (en) | Anti-kit antibodies and methods of use thereof | |
HK1108702A1 (en) | Ephb receptor-binding peptides ephb | |
CL2011001131A1 (es) | Uso de una formulacion que sirve para preparar un medicamento para una inyeccion, que reduce al minimo la inflamacion en el sitio de la inyeccion de un anticuerpo, y donde la formulacion comprendeun anticuerpo 2h7 y variantes del anticuerpo y polivinilpirrolidona (pvp) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |